Background Anlotinib showed significant survival benefits in advanced non‐small cell lung
cancer (NSCLC) patients as a third‐or further‐line treatment in the ALTER0303 trial. We …

Background Anlotinib hydrochloride, an oral tyrosine kinase inhibitor targeting VEGFR,
FGFR, PDGFR, and c-kit, showed promising efficacy in a phase 2 study. Here, we evaluated …

Background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer
and its incidence seriously affects human health. The purpose of this study was to evaluate …

e21173 Background: Anlotinib is a novel oral small molecule TKI with anti-tumor vascular
generation and growth inhibition effects, targeting VEGFR, PDGFR, FGFR, and c-kit. It has …

Background Antiangiogenic therapy combined with PD-1/PD-L1 inhibitors has shown
excellent efficacy in advanced NSCLC pts. The ALTER 0303 trial showed that anlotinib …

Background: Anlotinib (AL3818) is a novel multitarget tyrosine kinase inhibitor, inhibiting
tumour angiogenesis and proliferative signalling. The objective of this study was to assess …

Purpose Anlotinib is an anti-angiogenetic multi-targeted tyrosine kinase inhibitor. This study
aimed to evaluate the efficacy and safety of anlotinib in advanced non-small cell lung cancer …

Objective: To evaluate the efficacy and safety of anlotinib in patients with advanced non-
small cell lung cancer (NSCLC). Methods: Patients with stage ⅢB/Ⅳ NSCLC who …

Background No standard treatment exists for non-small cell lung cancer (NSCLC) with
failure of first-line therapies. Combination of antiangiogenic therapy and immune checkpoint …

Background Anlotinib hydrochloride, a novel multi-targeted tyrosine kinase inhibitor (TKI)
was found to exhibit excellent inhibitory efficiency on a variety of receptor tyrosine kinases …